ReviewCurrent HIV/AIDS reports2026
Epigenetic aging is a hallmark of HIV pathogenesis and phenotypic outcomes.
Review in Current HIV/AIDS reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- BRD proteins in human retroviral infection: emerging evidence from HIV-1 and future perspectives for HTLV-1.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purpose of reviewTo provide a summary of epigenetic studies of HIV with a focus on DNA methylation-based biomarkers of aging. We examine first, second, and third generation epigenetic clocks, and how these biomarkers relate to molecular and phenotypic outcomes in people with HIV (PWH). RECENT
findingsCurrent studies show novel associations of epigenetic aging with cellular senescence, human endogenous retroviruses and transposable elements, metabolic changes, neurological injury, and sex-based aging differences in PWH. First-generation epigenetic clocks of chronological age show an average of 5–7 years of age acceleration in PWH compared to people without HIV. Second-generation epigenetic clocks demonstrate accelerated aging-related phenotypes in PWH, including greater predicted morbidity and mortality. Third-generation epigenetic clocks provide novel insights into mechanisms of aging including DNA damage and beneficial adaptations, human endogenous retroviruses and transposable DNA elements, and distinct aging patterns in different organ systems. Epigenetic clocks offer the promise of accurate, quantitative biological markers of aging in research and clinical settings for PWH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.